Item 1.01: | Entry into a Material Definitive Agreement |
On May 3, 2023, Cardinal Health, Inc., (the “Company”) entered into a First Amendment (the “Amendment”) to the Cooperation Agreement (the “Cooperation Agreement”) dated September 5, 2022 by and among Elliott Associates, L.P., Elliott International, L.P. and Elliott International Capital Advisors Inc. and the Company. The Amendment extends the term of the Cooperation Agreement until the later of (i) July 15, 2024 and (ii) 11:59 p.m., Eastern Time, on the date that is five days following the date on which the Investor Designee (as such term is defined in the Cooperation Agreement) or the Investor Designee’s successor ceases to serve on, or resigns from, the Company’s Board of Directors. In connection with this extension, our Board of Directors has extended the term of the Business Review Committee until July 15, 2024.
Except as provided above, the Amendment does not modify the Cooperation Agreement in any way, and the Cooperation Agreement, as amended, shall remain in full force and effect.
The foregoing summary of the Amendment is qualified by reference to the full text of the Amendment, a copy of which is attached as Exhibit 10.1 hereto and is incorporated by reference.
Item 2.02: | Results of Operations and Financial Condition |
On May 4, 2023, Cardinal Health, Inc. (the “Company”) issued a news release announcing its results for the quarter ended March 31, 2023. A copy of the news release is included as Exhibit 99.1 to this report.
Item 7.01: | Regulation FD Disclosure |
During a webcast scheduled to be held at 8:30 a.m. Eastern time on May 4, 2023, the Company’s Chief Executive Officer and Chief Financial Officer will discuss the Company’s results for the quarter ended March 31, 2023 and outlook for the fiscal year ending June 30, 2023. The slide presentation for the webcast will be available on the Investors page at ir.cardinalhealth.com. An audio replay of the webcast also will be available on the Investors page at ir.cardinalhealth.com.
Item 9.01: | Financial Statements and Exhibits |
(d) Exhibits
2